Why the study?
Is anti-thrombomodulin antibody a sensitive marker for vascular neoplasms compared to established endothelial markers?
Is anti-thrombomodulin antibody a sensitive marker for vascular neoplasms compared to established endothelial markers?
Anti-thrombomodulin antibody is a sensitive marker for vascular neoplasms, though slightly less sensitive than anti-CD34, it may offer specificity advantages.
Answers are grounded in this paper and cite their sources.
Anti-TM may complement CD34 in vascular neoplasm IHC; leaves open specificity advantages in diagnostic pathology.
BACKGROUND: Various endothelial markers are available for the evaluation of vascular tumors and malformations, including anti CD34, anti-CD31, von Willebrand factor (vWF), and anti-thrombomodulin (anti-TM) antibodies. All have their limitations, and we sought to compare the utility of anti-TM antibody as a marker for several types of vascular neoplasms vs. previously established endothelial markers. METHODS: We examined immunostaining profiles of 30 capillary hemangiomas, 10 pyogenic granulomas, five tufted angiomas, 17 Kaposi's sarcomas, and nine angiosarcomas. Immunostains for TM, CD34, and vWF were carried out using a labeled streptavidin-biotin peroxidase detection system. RESULTS: Anti-TM antibody showed moderately intense immunostaining in 89% of benign and malignant vascular neoplasms. Anti-CD34 antibody showed moderate to diffuse immunostaining in 98% of vascular neoplasms, and vWF showed weak focal staining in 84% of all vascular neoplasms examined. CONCLUSION: Anti-TM antibody proved to be a sensitive marker for both benign and malignant vascular neoplasms. While not as sensitive as anti-CD34, it may have some advantages in specificity that would make it a more reliable vascular tumor marker in certain situations.
No takes yet. Share an insight, caveat, or question.
Manning et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: